Proteome Regulatory News (PRM)

Proteome Sciences plc

Science and Technology Award for TMT at HUPO World Congress

12th September 2014. Proteome Sciences is delighted that HUPO (Human Proteome Organisation) has announced that the Science and Technology Award for the commercialisation of isobaric mass tagging technologies, including our TMT® isobaric mass tags for labelling samples in mass spectrometers, is to be presented at the forthcoming HUPO World Congress in Madrid. Dr Andrew Thompson, Head of Chemical Proteomics at Proteome Sciences is amongst the team being honoured. Dr Thompson was an original inventor of TMT® proteomics and he has also worked on the application of isobaric tags in genomics and MALDI imaging. TMT® chemical tags, distributed through Thermo Scientific, have become the global market leader and that position will be extended through a continuing program of new product introductions.

Dr Ian Pike, Chief Operating Officer commented:

"This award from HUPO to the team leading the commercial development of TMT® is a welcome recognition of the innovation that Proteome Sciences plc has brought to the field of proteomics.

Over the last six years we have developed the largest portfolio of TMT® isobaric tagging reagents for a wide range of biological experiments. TMT® 10-plex provides the highest multiplexing capability currently available and we will continue to deliver new reagents that further expand the range of tags.

Using sophisticated TMT® workflows we are able to offer our clients the same level of innovation in our proteomics discovery and validation services through SysQuant® for cell signalling pathway analysis and TMT®-MS3 for high-throughput plasma and CSF proteomics."

- Ends -

For further information please contact:

Notes for editors:

About Proteome Sciences plc (www.proteomics.com)

Proteome Sciences is a global leader in applied proteomics and peptidomics offering high sensitivity, proprietary technologies for protein and peptide biomarker discovery, validation and assay development. The Company is headquartered in Cobham, UK, with laboratory facilities in London and Frankfurt.

Proteome Sciences' proprietary research has discovered a large number of novel protein biomarkers in key human diseases and is focused mainly in neurological/neurodegenerative conditions and in cancer. It has discovered and patented blood biomarkers in Alzheimer's disease, stroke, brain damage and lung cancer for diagnostic and treatment applications that are available for license or have already been outlicensed.

The Company's PS Biomarker Services division provides outsourced proteomics services and proprietary biomarker assays to pharmaceutical, biotechnology and diagnostics companies from its ISO 9001:2008 facility in Frankfurt, Germany.